ClinicalTrials.gg
CompletedNCT01306123Updated Nov 3, 2014

Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration

A Phase 1 interventional study of Nascobal nasal spray (cyanocobalamin, USP) and Vitamin B12-ratiopharm N, injection solution in Focus: Bioavailability, sponsored by Swedish Orphan Biovitrum. Completed at 1 site in Sweden. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-03.

Sponsored by Swedish Orphan Biovitrum · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the relative bioavailability of Nascobal Nasal Spray as compared to an IM injection of cyanocobalamin (European reference product).

Read the detailed description

This is an open-label, randomized, single-dose, two-way crossover study. The study consists of a screening visit, two 4-days confinement periods and a follow-up telephone call. The two confinement periods will be separated by a washout period of at least 28 days.

02

Conditions studied

  • Focus: Bioavailability

Keywords

  • bioavailability
  • pharmacokinetics
  • cyanocobalamin
  • intranasal
  • intramuscular
03

In context

Lead sponsor

Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female and male voluteers
  • 18-40 years of age
  • between 18.5 and 30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or lactating
  • History of metabolic, hepatic, renal, haematological, pulmondary, cardiovascular, gastrointestinal, urological, neurological or phychiatric disorders
  • Serum vitamin B12 \<=250 pmol/L or MMA >=0.40 umol/L
  • Evidence of significant intranasal pathology
  • Nasal congestion, allergic rhinitis or upper respiratory tract infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Nascobal nasal spray (cyanocobalamin USP)

    One single administration of intranasal cyanocobalamin (initially)

    Drug: Nascobal nasal spray (cyanocobalamin, USP)

  • Active comparator
    Vitamin B12-ratiopharm N, injection solution

    One single injection of IM cyanocobalamin (initially)

    Drug: Vitamin B12-ratiopharm N, injection solution

Interventions

06

What researchers measure

Primary outcomes

  1. Relative bioavailability

    Relative bioavailability (Frel) based on the area under the serum concentration-time curve during 72 hours (AUC0-72h) for the test and reference products.

    Time frame: 0-72 hours

Secondary outcomes

  1. Additional PK characteristics

    Maximum serum concentration (Cmax), time of Cmax (tmax) and AUC0-24h.

    Time frame: 0-72h

07

Study locations

1 site
  • Karolinska Trial Alliance, Karolinska University Hospital, Huddinge
    Stockholm, Stockholm County 141 86, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 1, 2011
Start
Feb 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Nov 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01306123
Responsible party
Sponsor
First posted
Mar 1, 2011
Start date
Feb 2011
Primary completion
May 2011
Completion
May 2011
Last update
Nov 3, 2014

Study contacts

Nabil Al-Tawil, MD, PhD
principal investigator · Karolinska Trial Alliance

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin B 12

Start the discussion